Molecular mass: 1,472.41 g/mol PubChem compound: 131704321
Indium(111In)pentetreotide specifically binds to receptors for somatostatin. After radiolabelling pentetreotide with indium( 111In)chloride, the solution obtained is indicated for use as adjunct in the diagnosis and management of receptor bearing gastro-entero-pancreatic neuroendocrine (GEP) tumours and carcinoid tumours, by aiding in their localisation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| V09IB01 | Indium (111In) pentetreotide | V Various → V09 Diagnostic radiopharmaceuticals → V09I Tumour detection → V09IB Indium (111In) compounds |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| OCTREOSCAN Kit for radiopharmaceutical preparation | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Indium ¹¹¹In pentetreotide is an active ingredient of these brands:
Austria (AT)
France (FR)
Ireland (IE)
Japan (JP)
Singapore (SG)
Spain (ES)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
